The Medicines Patent Pool and ViiV Healthcare have struck a voluntary licensing deal that will allow MPP partners to develop, manufacture and supply generic versions of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in 90 low-income, lower middle-income and Sub-Saharan African countries.
“This announcement comes just seven months after the first regulatory approval of cabotegravir LA for PrEP in the world, by...





